Clinical Trial Update: DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating DOC1021 dendritic cell immunotherapy for refractory melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DOC1021 Dendritic Cell Immunotherapy (DOC1021)

Snippet

Sponsor: Diakonos Oncology Corporation | Conditions: Refractory Melanoma | Phase 1, Phase 2 | Status: RECRUITING